Compare CRSP & QBTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | QBTS |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 6.0B |
| IPO Year | 2016 | 2022 |
| Metric | CRSP | QBTS |
|---|---|---|
| Price | $50.20 | $11.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 17 |
| Target Price | ★ $85.63 | $34.65 |
| AVG Volume (30 Days) | 1.5M | ★ 13.0M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $1,052.09 | $72.74 |
| Revenue Next Year | $273.88 | $89.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $44.12 | $11.35 |
| 52 Week High | $70.74 | $37.62 |
| Indicator | CRSP | QBTS |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 28.02 |
| Support Level | $45.61 | N/A |
| Resistance Level | $60.71 | $21.98 |
| Average True Range (ATR) | 2.51 | 0.68 |
| MACD | -0.48 | -0.35 |
| Stochastic Oscillator | 8.96 | 9.47 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
D-Wave Quantum Inc is in the development and delivery of quantum computing systems, software, and services, and it is the commercial supplier of quantum computers and the only company building both annealing quantum computers and gate-model quantum computers. It delivers customer value with practical quantum applications for problems as diverse as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, cybersecurity, fault detection, and financial modeling. Its annealing quantum computers are accessible through the company's LeapTM cloud service.